Tumor Imaging

Our first Investigational New Drug Application (IND) application in India based on U.S. licensed technology is for a tumor imaging product. This product has received Indian approval for a combination Phase I/II clinical trial. Once adequate clinical data is obtained, EndogenX intends to seek out-license or co-development partners to rapidly expand the application of this diagnostic.

Today, should your physician suspect a cancerous a tumor, the tumor will first be confirmed throught imaging. To determine if it is malagnant, a biopsy is generally performed. However, one study found that as many as two of every three breast biopsies were begnin. If your physician could determine the status of the tumor at the time of imaging, then he would only need to conduct a biopsy on those lesions determined by imaging to be malagnant. That biopsy would identify the type of cancer and assist in determining the method of treatment.

END-1620 is a highly selective peptide agonist of endothelin-B receptors, which can stimulate receptors on endothelial cells, the innermost layer of cells lining the blood vessels. This technology takes advantage of the fact that the blood supply to tumors is different than the blood supply to healthy organs. Blood vessels in the growing part of tumors are relatively devoid of smooth muscle covering and are rich in endothelial cells. Therefore, by stimulating the endothelial-B receptors present on the endothelial cells, END-1620 should selectively increase tumor blood flow, including breast, lung, and prostate tumors, while sparing healthy tissue. END-1620 is being developed as an adjunct to PET Scans. Either alone or in conjunction with a tumor marker, END-1620 holds the promise to not only identify malignant tumors, but to also differentiate them from benign tumors.

	Research		PreClinical		Clinical		Market
ENDG4010 Tumor Imaging